Deferoxamine reduces tissue injury and lethality in LPS-treated mice

International Journal of Immunopharmacology

Volumn 22, Issue 8, 2000, Pages 635-644

  Vulcano, Marisa ^a   Meiss, Roberto P ^b   Isturiz, Martín A ^a  

^a INST DE INVEST HEMATOLOGICAS   (Argentina)

^b ACADEMIA NACIONAL DE MEDICINA   (Argentina)

Author keywords

Deferoxamine; Lipopolysaccharide; Sepsis; TNF

Indexed keywords

DEFEROXAMINE; DEFEROXAMINE MESYLATE; FERRIOXAMINE; FREE RADICAL; GALACTOSAMINE; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; SCAVENGER; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL MODEL; ARTICLE; BACTERIAL INFECTION; CONTROLLED STUDY; ESCHERICHIA COLI; FEMALE; MALE; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SENSITIZATION; SEPTIC SHOCK; TISSUE INJURY;

ANIMALS; DEFEROXAMINE; GALACTOSAMINE; INTERLEUKIN-1; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED BALB C; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034257176     PISSN: 01920561     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0192-0561(00)00026-6     Document Type: Article

References (49)

1. Parrillo J.E. Septic shock in humans: advances in the understanding of pathogenesis cardiovascular dysfunction and therapy. Ann. Intern. Med. 113:1990;227-242.
2. Bone R.C. Sepsis, the sepsis syndrome, multi-organ failure: a plea for comparable definitions. Ann. Intern. Med. 114:1991;332-333.
3. Glauser M.P., Zanetti G., Baumgartner J.D., Cohen J. Septic shock: pathogenesis. Lancet. 338:1991;732-736.
4. Hurley J.C. Concordance of endotoxemia with Gram-negative bacteremia in patients with Gram-negative sepsis: a metaanalysis. J. Clin. Microb. 32:1994;2120-2127.
5. Morrison D.C., Ryan J.L. Endotoxins and disease mechanisms. Ann. Rev. Med. 38:1987;417-432.
6. Cross A.S., Opal S.M. Endotoxin's role in Gram-negative bacterial infection. Curr. Opin. Infect. Dis. 8:1995;156-163.
7. Brigham K.L., Meyrick B. Interactions of granulocytes with the lungs. Cir. Res. 54:1984;623-635.
8. Nolan J.P. The role of endotoxin in liver injury. Gastroenterology. 69:1975;1346-1356.
9. Franke F.E. Action of toxic doses of the polysaccharide from Serratia Marcescens (Bacillus prodigiosus) on the dog and guinea pig. J. Natl. Cancer. Inst. 5:1944;185-193.
10. Dinarello C.A. Cytokines as mediators in the pathogenesis of septic shock. Curr. Top. Microbiol. Immunol. 216:1996;133-165.
11. Tracey K.J., Beutler B., Lowry S.F., Merryweather J., Wolpe, et al. Shock and tissue injury induced by recombinant cachectin. Science. 234:1986;470-474.
12. Beutler B., Cerami A. Tumor necrosis, cachexia, shock and inflammation: a common mediator. The biology of cachectin/TNF-α. A primary mediator of the host response. Ann. Rev. Biochem. 57:1988;505-518.
13. Beutler B., Cerami A. The biology of cachectin/TNF-α primary mediator of the host response. Ann. Rev. Immunol. 7:1989;625-655.
14. Vassalli P. The pathophysiology of tumor necrosis factors. Ann. Rev. Immunol. 10:1992;411-452.
15. Casey L.C., Balk R.A., Bone R.C. Plasma cytokine and endotoxin levels correlate with survival in patients with sepsis syndrome. Ann. Int. Med. 119:1993;771-778.
16. Wallach D., Holtmann H., Engelmann H., Nophar Y. Sensitization and desensitization to lethal effects of tumor necrosis factor and IL-1. J. Immunol. 140:1988;2994-2999.
17. Fong Y., Moldawer L.L., Marano M., Manogue K., Tracey K.J., et al. Cachectin/TNF or IL-1β induces cachexia with redistribution of body proteins. Am. J. Physiol. 256:1989;659-665.
18. Hoffmann W.D., Suffredini A.F., Eichacker P.Q., Danner R.L. Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis. NIH Conference. Ann. Intern. Med. 120:1994;771-783.
19. Ziegler E.J., Mc Cutchan J.A., Fierer J., Glauser M.P., Sadoff J.C., et al. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N. Engl. J. Med. 307:1982;1225-1230.
20. Warren H.S., Danner R.L., Munford R.S. Sounding board: anti-endotoxin antibodies. N. Engl. J. Med. 326:1992;1153-1157.
21. Fisher C.J., Opal S.M., Dbainaut J.F., Stephens S., Zimmerman J.L., et al. Influence of an anti-tumor necrosis factor antibody on cytokine levels in patients with sepsis. Crit. Care. Med. 21:1993;318-327.
22. Fisher C.J., Slotner G.J., Opal S.M., Pribble J.P., Bone R.C., et al. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit. Care. Med. 22:1994;12-21.
23. Sadoff J. Soluble TNF receptors. Presented at the Third International Congress of the Immune Consequences of Trauma, Shock and Sepsis: Mechanisms and Therapeutic Approaches. Munich, Germany, 5 March :1994.
24. Ward P.A., Warren J.S., Johnson K.J. Oxygen radicals, inflammation, and tissue injury. Free. Rad. Biol. Med. 5:1988;403-408.
25. Remick D.G., Villarete L. Regulation of cytokine gene expression by reactive oxygen and reactive nitrogen intermediates. J. Leuk. Biol. 59:1996;471-475.
26. Schreek R., Albermann K., Baeuerle P.A. Nuclear factor kappa B: an oxidative stress-responsive transcription factor of eukaryotic cells. Free Rad. Res. Commun. 17:1992;221-237.
27. Fox E.S., Brower J.S., Bellezzo J.M., Leingang K.A. N-acetylcysteine and alpha tocopherol reverse the inflammatory response in activated rat Kupffer cells. J. Immunol. 158:1997;5418-5423.
28. Galley H.F., Howdle P.D., Walker B.E., Webster N.R. The effects of intravenous antioxidants in patients with septic shock. Free Radic. Biol. Med. 23:1997;768-774.
29. Lalonde C., Nayak U., Hennigan J., Demling R.H. Excessive liver oxidant stress causes mortality in response to burn injury combined with endotoxin and is prevented with antioxidants. J. Burn. Care. Rehabil. 18:1997;187-192.
30. Halliwell B., Gutteridge J.M. Oxygen toxicity, oxygen radicals, transition metals and disease. Biochem. J. 219:1984;1-14.
31. Simeonova P.P., Luster M.I. Iron and reactive oxygen species in the asbestos-induced tumor necrosis factor-α response from alveolar macrophages. Am. J. Resp. Cell Mol. Biol. 12:1995;676-683.
32. Kamp D.W., Graceffa P., Pryor W.A., Weitzman S.A. The role of free radicals in asbestos-induced diseases. Free Rad. Biol. Med. 12:1992;293-315.
33. Wang A.M., Creasey A.A., Ladner M.B., Lin L.S., Strickler, et al. Molecular cloning of the complementary DNA for human tumor necrosis factor. Science. 228:1985;149-154.
34. Galanos C., Freudenberg M.A., Reutter W. Galactosamine-induced sensitization to the lethal effects of endotoxin. Proc. Natl. Acad. Sci. USA. 76:1979;5939-5943.
35. Lehmann V., Freudenberg M.A., Galanos C. Lethal toxicity of lipopolysaccharide and tumor necrosis factor in normal and D-galactosamine-treated mice. J. Exp. Med. 165:1987;657-663.
36. Goode H.F., Cowley H.C., Walker B.E., Webster N.R. Decreased antioxidant status and increased lipid peroxidation in patients with sepsis and secondary organ dysfunction. Crit. Care Med. 23:1996;646-651.
37. Galley H.F., Davies M.J., Webster N.R. Ascorbyl radical formation in patients with sepsis: Effect of ascorbate loading. Free Rad. Biol. Med. 20:1995;139-143.
38. Galley H.F., Davies M.J., Webster N.R. Xanthine oxidase activity and free radical generation in patients with sepsis syndrome. Crit. Care. Med. 24:1996;1649-1653.
39. Vulcano M., Alves Rosa M.F., Breyer I., Isturiz M.A. Hydroxyl radical scavengers inhibit TNF-α production in mononuclear cells but not in polymorphonuclear leukocytes. Intern. J. Immunopharmacol. 20:1998;709-722.
40. Scales W.E., Chensue S.W., Otterness I., Kunkel S.L. Regulation of monokine gene expression: prostaglandin E2 suppreses tumor necrosis factor but not interleukin-1 alpha or beta mRNA and cell-associated bioactivity. J. Leuk. Biol. 45:1989;416-421.
41. Endres S. Fulle H.J., Sinha B, Stoll D, Dinarello, et al. Cyclic nucleotides differentially regulate the synthesis of tumour necrosis factor-α and interleukin-1β in human mononuclear cells. Immunology 1991; 72: 56-60.
42. Breyer I., Vulcano M., Alves Rosa M.F., Isturiz M.A. Neutrófilos humanos (PMN) inducen la liberación de lipopolisacáridos (LPS) de bacterias Gram-negativas. Medicina (Buenos Aires). 58:1998;61-64.
43. Shalaby M.R., Palladino M.A., Hirabayashi S.E., Eessaln T.E., Lewis G.D., et al. Eceptor binding and activation of polymorphonuclear neutrophils by tumor necrosis factor. J. Leuk. Biol. 41:1987;196-204.
44. Pohlman T.M., Stannes K.A., Beatty P.G., Ochs H.D., Harlan J.M. An endothelial cell surface factor (s) induced in vitro by lipopolysaccharide, interleukin-1 and tumor necrosis factor-alpha increases neutrophil adherence by a Cdw18-dependent mechanism. J. Immunol. 136:1986;4548-4553.
45. Nawroth P.P., Stern D.M. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J. Exp. Med. 163:1986;740-745.
46. Tsujimoto M., Yokota S., Vilcek J., Weissmann G. Tumor necrosis factor provokes superoxide anion generation from neutrophils. Biochem. Biophys. Res. Commun. 137:1986;1094-1100.
47. Ziegler-Heitbrock H.W.L. Molecular mechanism in tolerance to lipopolysaccharide. J. Inflammation. 45:1995;13-26.
48. Renz H., Gong J.H., Schmidt A., Nain M., Gemsa D. Release of tumor necrosis factor α from macrophages. J. Immunol. 141:1988;2388-2393.
49. Palermo M.S., Alves-Rosa F., Fernández Alonso G., Isturiz M.A. Fcγ receptor-dependent clearance is enhanced following lipopolysaccharide in vivo treatment. Immunology. 92:1997;536-543.